Prima Shifts Focus To LAG-3 After Immutep Deal
This article was originally published in PharmAsia News
The Australian immuno-therapeutics developer Prima BioMed has had a change of focus in recent months since buying Paris-based Immutep in late 2014. Prima’s lead product used to be its CVac cancer vaccine, but it has now shifted strategic priority to an LAG-3 immune checkpoint receptor that came with the acquisition.
You may also be interested in...
Deal Watch: Pfizer Offloads Troubled ADHD Products To Manufacturer Tris
Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.
Phylogica Surges On Early CPP Cancer Results
Phylogica is continuing its strong financial year, with the company’s shares surging after it announced that a pilot study for its cell-penetrating peptides (CPPs) showed these were able to kill drug-resistant breast cancer cells in vivo, when linked with the cancer drug Omomyc.
OncoSil Surges On Cancer Device CE Mark Plans
Australian medical device developer OncoSil Medical Limited saw its shares surge by a third on Mar. 16 after it announced that it would file for the CE Mark in both pancreatic and liver cancer indications in the second half of the year, on the back of clinical data that demonstrate its eponymous proprietary device technology is effective against two solid tumor types.